Cytori Therapeutics, Inc. (NASDAQ: CYTX) is committed to becoming the global leader in regenerative medicine. The company focuses on providing patients with new options for reconstructive and aesthetic surgery, developing treatments for cardiovascular disease, and banking adipose-derived, adult stem and regenerative cells (ADRCs). To meet its objective, Cytori developed Celution® Technology to separate and concentrate a patient’s own ADRCs for delivery back to the same patient in a single surgical procedure. For further information, visit the Company’s web site at www.cytoritx.com.
- 18 years ago
QualityStocks
Cytori Therapeutics, Inc. (NASDAQ: CYTX)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Information Services Group (NASDAQ: III) Rings Nasdaq Closing Bell To Mark 20th Anniversary
Information Services Group (NASDAQ: III) will mark its 20th anniversary by ringing the closing bell on May 5, 2026, at…
-
QualityStocksNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Develops Cross-Language AI Model For Intoxication Detection
This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO;…
-
QualityStocksNewsBreaks – Forward Industries, Inc. (NASDAQ: FWDI) Invests In OnRe And Plans $25M Deployment Into Tokenized Reinsurance Platform
Forward Industries (NASDAQ: FWDI) announced a strategic investment in onchain reinsurance company OnRe as part of its $5 million Series…